TOP    Events & Outreach    R-CCS Cafe    The 234th R-CCS Cafe - part 3

Title

Development of drug discovery AI platform collaborated with pharmaceutical companies

Details
Date Mon, Sep 5, 2022
Time 4:40 pm - 5:00 pm (5 pm - 5:20 pm Discussion, 5:20 pm - Free discussion (optional))
City Online
Place

Online seminar on BlueJeans

  • If you are not affiliated with R-CCS and would like to attend R-CCS Cafe, please email us at r-ccs-cafe[at]ml.riken.jp.
Language Presentation Language: English
Presentation Material: English
Speakers

Teruki HONMA

Medicinal Chemistry Applied AI Unit
Unit Leader

photo: Teruki HONMA

Abstract

Since the late 2010s, applications of Artificial Intelligence (AI) to drug discovery have become very important issues in pharmaceutical industry. HPC- and AI-driven Drug Development Platform Division have organized a consortium (LINC) with pharmaceutical and IT companies to build AI technologies including GCN-based prediction models, MCTS-based chemical structure generation models. After the first phase of LINC, AMED and our division started a new national project named DAIIA collaborated with 18 pharmaceutical companies. Using more than 10 million of data, we have been constructing more accurate and applicable AI models for drug discovery.

Important Notes

  • Please turn off your video and microphone when you join the meeting.
  • The broadcasting may be interrupted or terminated depending on the network condition or any other unexpected event.
  • The program schedule and contents may be modified without prior notice.
  • Depending on the utilized device and network environment, it may not be able to watch the session.
  • All rights concerning the broadcasted material will belong to the organizer and the presenters, and it is prohibited to copy, modify, or redistribute the total or a part of the broadcasted material without the previous permission of RIKEN.

(Aug 30, 2022)